David Bonita resigned as a class II independent director of Loxo Oncology Inc., effective Dec. 22.
Bonita's resignation is not the result of any disagreement with the company on any matter relating to its operations, policies or practices.
Loxo Oncology director resigns
Gauging Supply Chain Risk In Volatile Times
Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals
The Future of Risk Management Digitization in Credit Risk Management
Climate Credit Analytics: Diving into the model
Loxo Oncology director resigns
- Author Tayyeba Irum
- Theme Healthcare & Pharmaceuticals
- Author
- Tayyeba Irum
- Theme
- Healthcare & Pharmaceuticals